A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age

Recruiting

Phase 3

MF59-Adjuvanted VaccineA Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age

Sponsor:

Seqirus

Code:

NCT06087640

Conditions

Influenza, Human

Eligibility Criteria

Sex: All

Age: 65+

Healthy Volunteers: Accepted

Interventions

aQIV or aTIV

QIV or TIV

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-30. This information was provided to ClinicalTrials.gov by Seqirus on 2025-11-12.